Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials

J Paul Banga, Claus H Nielsen, Jacqueline A Gilbert, Daniel El Fassi, Laszlo Hegedus

    20 Citationer (Scopus)

    Abstract

    Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.
    OriginalsprogEngelsk
    TidsskriftThyroid
    Vol/bind18
    Udgave nummer9
    Sider (fra-til)973-81
    Antal sider9
    ISSN1050-7256
    DOI
    StatusUdgivet - 1 sep. 2008

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials'. Sammen danner de et unikt fingeraftryk.

    Citationsformater